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Cadaveric Liver Transplantation: With Particular 
Reference to Hepatitis C Virus 
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Adriana Zeevi, 1,3 Noriko Murase/,2 and Thomas E. Starz[l,2,4 -
We have proposed that the mechanisms of alloengraftment and variable acquired tolerance can be facilitated by 
minimum posttransplant immunosuppression. It was further suggested that the efficacy of minimalistic treat-
ment could be enhanced by preoperative recipient conditioning with an antilymphoid antibody preparation. A 
total of 76 adults (38 hepatitis C virus [HCY]-, 38 HCY+) were infused with 30 mg alemtuzumab before primary 
cadaveric liver transplantation and maintained afterward on daily monotherapy unless breakthrough rejection 
mandated additional agents. In stable patients, the intervals between tacrolimus doses were lengthened ("spaced 
weaning") after approximately 4 months. Eighty-four contemporaneous_nonlymphoid-depleted liver recipients 
(58 HCY-, 26 HCY+) were treated with conventional postoperative im~unosuppressionK The overall incidence 
of rejection was similar with the two strategies of immunosuppression. With follow-ups of 14 to 22 months, 
patient and primary graft survival in HCY- cases are 97% and 90%, respectively, with alemtuzumab depletion 
plus minimal immunosuppression versus 71 % and 70%, respectively, under conventional immunosuppression. 
In HCY+ recipients, current patient and graft survival in the alemtuzumab-pretreated group are 71 % and 70% 
versus 65% and 54%, respectively, under conventional treatment. With both strategies of immunosuppression, 
the adverse effect of preexisting HCY on survival parameters and graft function already was significant at the 
I-year milestone, but its extent was not evident until the second year. With or without HCY, 62% of the 64 
surviving lymphoid-depleted patients are on spaced immunosuppression, and four patients receive no immuno-
suppression. Lymphoid depletion with alemtuzumab and minimalistic maintenance immunosuppression is a 
practical strategy of liver transplantation in HCY- recipients but not HCY+ recipients. 
(Transplantation 2004;78: 966-971) 
I n 2001, we proposed that the heavy multidrug immuno-
suppression given in most centers from the time of organ 
transplantation could erode the seminal engraftment mech-
anism of clonal exhaustion-deletion (Fig. lA) (1). Avoidance 
of this self-defeating consequence of treatment by the use of 
minimum posttransplant immunosuppression has been 
counterintuitive because of concern about a potentially 
higher rate of acute rejection. To avoid this penalty, we sug-
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gested the joint application of a second therapeutic principle, 
that is, reduction of the anticipated antidonor response into a 
more readily deletable range by lymphoid depletion of the 
recipient Defore exposure to don,?r antigen (Fig. lB) (1). En-
couraging results were obtained in our first series of organ 
recipients in whom both theraphltic principles were applied. 
The lymphoid depletion was performed in the first cases with 
rabbit antithymocyte globulin (Thymoglobulin) (2,3). 
Here, we report the use of alemtuzumab (Campath) 
instead of antithymocyte globulin for the pretreatment of 76 
recipienfs of cadaveric livers. Alemtuzumab, which was de-
veloped by Hale, Waldmann, al'ld Dyer (4), causes profound 
depression of the lymphocyte lineages without causing major 
declines in platelets. Its efficacy in kidney transplantation was 
first reported by Calne et al. (5) and subsequently confirmed 
by Stuart et al. (6), Knechtle et al. (7), and Kirk et al. (8). 
Alemtuzumab also has been used by Tzakis et al. (9) for in-
testinal and liver transplantation. In most of the foregoing 
experience, two doses of alemtuzumab were given, the first 
intraoperatively and the second several days later. In our pa-
tients, a single dose was given before transplantation. 
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METHODS 
Immunosuppression 
Alemtuzumab-Tacrolirnus 
Seventy-six adults underwent primary cadaveric liver 
transplantation between September 2002 and April 2003 after 
a 30-mg infusion of alemtuzumab; 1 or 2 g of methylpred-
nisolone was given simultaneously to prevent cytokine reac-
tions. Within 1 day, the lymphocyte counts decreased from 
1,056+712 mm3 to 130::t135 mm3• Recovery from the pro-
found depression began by 1 to 2 weeks. At 3 and 6 months, 
the mean lymphocyte counts were 619::t522 mm3 and 
685::t578 mm3, respectively. Even at 1 year, there was still a 
residual depression of CD4 + and to a lesser extent C08 + 
cells. As other investigators have observed, the rebound of B 
cells preceded that of the other mononuclear lineages and was 
restored to above baseline at 3 months. Platelet counts were 
not significantly depressed in comparison with those in con-
ventionally immunosuppressed liver recipients. 
Twice-daily tacrolimus was begun on the day after trans-
plantation, with a target trough level of 10 ng/mi. With sus-
pected drug toxicity (most commonly nephrotoxicity or neuro-
toxicity), cycIosporine or sirolimus was substituted for 
tacrolimus in a few patients. If rejection occurred in the first 4 
months, additional immunosuppression was added to the 
monotherapy, but only for as long as necessary to restore stable 
graft function. At approximately 4 months, the twice-daily doses 
of tacrolimus (or the substitute monotherapeutic agent) were 
consolidated to one dose per day in patients who had been stable 
on the single drug therapy for at least 60 days. One to 2 months 
later, dose frequency was reduced to every other day and subse-
quently to longer intervals when possible. If rejection occurred 
while weaning, daily treatment with the baseline drug was re-
sumed, and other agents were temporarily added. After recovery 
from the rejection, a search was reinstit}lted for the lowest pos-
sible daily immunosuppression. 
Examples of application of the algorithm are shown in 
Figure 2. Every other day dosing in the patient depicted in 
Figure 2A was begun 7.5 months after liver transplantation on 
September 12, 2002. By 14 months, the tacrolimus dosing had 
. been reduced to once per week, and at 15 months treatment 
was stopped. There was no evidence of rejection at any time 
during the 22 months of follow-up. In the case depicted in 
Figure 2B, rejection developed after dosing frequency was 
reduced to two times per week. The patient was given two 
boluses of prednisone, and daily tacrolimus was temporarily 
resumed. After 3 additional months, he was weaned to 3 doses 
per week and has been stable for the ensuing 9 months. 
Conventional Treatment 
Also between September 2002 and April 2003, 84 ca-
daver liver recipients did not have alemtuzumab infusion. 
These 84 recipients were treated with the generic strategy de-
picted in Figure lA. Tacrolimus and a 5-day cycle of methyl-
prednisolone were begun on the day of operation, beginning 
with 200 mg on the first day and ending on day 5 at 40 mg. 
Weaning thereafter was performed slowly. At 2 months, 90% 
of the surviving patients were still receiving 10 mg or more 
per day prednisone. In addition, mycophenolate mofetil was 
given from the time of operation in many cases. Spaced wean-
ing from the baseline drug (usually tacrolimus) was not a 
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primary objective, but an attempt was made to reach the low-
est maintenance daily level consistent with stable graft func-
tion. In a few cases, spaced weaning was attempted to relieve 
drug toxicity. 
Pathologic Studies of Rejection 
Biopsy specimens were obtained for suspicion of rejection 
or in preparation for weaning. In addition to conventional he-
matoxylin-eosin histopathology, special stains were used when 
indicated to study the extent of fibrosis (Masson Trichrome) or 
to visualize other points of interest. Biopsy findings were entered 
into standardized categories using the Banff schema (10). Pa-
tients with no biopsy samples and no clinical evidence of rejec-
tion were considered to be rejection-free. 
Statistical Analysis 
The populations were described using mean and stan-
dard deviation or frequencies and percentages. Survival esti-
mates were obtained using the Kaplan-Meier method. Al-
though this was in no sense a prospective, randomized trial, 
the significance of differences in survival and graft function at 
1 year between the two groups was determined by using a 
log-rank test and other variables compared by t test and chi-
square test. P values less than 0.05 were considered 
significant. 
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nGURE 1. Proposed effect of immunosuppression on 
tolerogenic mechanisms (1). (A) Subversion of clonal ex-
haustion-deletion by excessive posttransplant immunosup-
pression. (B) The stepwise effect of pretreatment (1) and 
minimal posttransplant immunosuppression (2) in reduc-
ing the antigraft response into a more deletable range (see 
text). (C) Alloengraftment achieved with minimal post-
transplant immunosuppression alone. 
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FIGURE 2. (A) Course of alemtuzumab-pretreated re-
cipient. Spaced weaning from tacrolimus monotherapywas 
started at 7.5 months and reduced progressively thereaf-
ter. After 15 months, treatment was stopped. (B) Interrup-
tion of weaning when rejection occurred after doses were 
reduced to 2 times/week. The patient was treated with 
three boluses of prednisone and temporarily returned to 
daily tacrolimus. Three months later, he was weaned to 
three doses per week and has been stable since. 
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RESULTS 
Case Selection 
Of the eight severely ill status 1 patients, seven were 
members of the conventional immunosuppression group 
(Table 1). In most of the others in this group, delays in liver 
allocation had left insufficient time for the alemtuzumab in-
fusion. With elimination of the infusion, the average cold 
ischemia time of the allografts in the conventional group was 
similar to the alemtuzumab group (Table 1). 
The incidence of hepatitis C virus (HCV)-associated 
disease was 50% in the alemtuzumab cohort versus 31 % in 
the conventional treatment group (P<O.Ol) (Table 1). 
Patient and Graft Survival 
Overall 
One-year patient survival of the alemtuzumab-pre-
treated patients was 87% versus 800/0 for the conventionally 
immunosuppressed patients (P=0.36, not significant [NSj). 
In the respective cohorts, I-year primary graft survival was 
82% versus 73% (P=0.26, NS). Notably, the results at 1 year 
and beyond were profoundly influenced by the presence or 
absence of HCV. 
Hepatitis C Virus Effect -
With follow-ups of 14 to 22 months (to July 1,2004), 
the lymphoid-depleted recipients without HCV continue to 
have the same 97% and 90% patient and primary graft sur-
vival recorded at 1 year (Table 2) . 
In contrast, two of the HCV+ recipients died at 14 and 
21 months of hepatic failure caused by recurrent disease. 
Thus, the current patient and graft survival in HCV+ cases are 
71 % and 70%, respectively. 
Viral replication was frequently associated with ale-
mtuzumab infusion. In the patient whose course is depicted 
in Figure 3, a striking increase in viral titer occurred 2 months 
after alemtuzurnab pretreatment and transplantation. The vi-
ralload then declined for the next half year, but after a repeat 
dose of alemtuzumab, there was a similar wave of viral repli-
cation (peak 92 million HCV IU). The patient is clinically well 
at present, but the 14-month biopsy revealed bridging 
fibrosis. 
TABLE 1. Recipient and donor "factors 
Alemtuzamab Conventional 
pretreated. immunosuppression 
n 76 84 
Case accrual 9112/02 -> 4/30/03 9112/02 ~ 4/30/03 
Recipient age (yr) 52±1O.2 . 53±10.6 
Male/female 27/49 29/55 
MELD at transplant 14.2±5.7 ; 14.9±7.3 
Hepatitis C 38 (50%), 26(31%) 
Status 1 patients 10%) 7 (8%) 
Donor age 47± 15.9 51 ± 18.2 
Cold ischemia 11.9±3.36 hr 11.8±3.43 hr 
HLA mismatch 4.5± 1.2 4.5± 1.1 
HLA, human leukocyte antigen: MELD, Model for End-Stage Liver Dis-
ease. 
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TABLE 2. Effect of hepatitis C virus on patient and 
primary graft survival after alemtuzurnab pretreatment 
versus conventional immunosuppression after follow-up 
of 13 to 21 months" 
Alemtuzwnab Conventional 
N=76 N=84 
Patient survival 
Overall 64/76 (84%) 67/84 (80%) 
Without HCV 37/38 (97%) 50/58 (86%) 
WithHCV 27/38 (71 %) 17/26 (65%) 
Graft survival 
Overall 60176 (79%) 60/84 (71%) 
WithoutHCV 34/38 (90%) 46/58 (79%) 
WithHCV 26/38 (70%) 14/26 (54%) 
• A statistical analysis of the effect ofHCV on survival and allograft func-
tion at the 1-yr milestone is contained in the text. 
HeV, hepatitis C virus. 
The deleterious consequences ofHCV were equally ap-
parent under conventional immunosuppression. In the 
HCV- recipients, the I-year patient and graft survival of 86% 
and 79% remain the same after 14 to 22 months. The 65% 
patient and 58% primary graft survival in the HCV+ cohort 
already were inferior at 1 year. Although no further deaths 
have occurred in this cohort, one of the I-year survivors un-
derwent retransplantation after 14 months. Thus, current 
graft survival is only 54%. 
Causes of Death 
The proximate causes of death under the two kinds of 
immunosuppression were much the same. Common themes 
were sepsis and multiple organ failure. 
Graft Function 
Alemtuzumab-Pretreated Cohort 
At the I-year milestone, the mean serum bilirubin of 
l.04±O.97 mg/dL of the HCV- recipients was half the 
2.5:t6.55 mg/dL of the surviving HCV+ patients bearing pri-
mary grafts (P<O.Ol). The current mean bilirubin is 
0.92:t0.76 mg/dL in the HCV- group versus 1.65:t2.85 
mg/dL in the HCV+ cohort. 
Conventional Immunosuppression Cohort. 
The current mean serum bilirubin ofO.68:t0.44 mg/dL 
in the HCV- cohort is half the l.24:t 1.35 mg/dL in the 
HCV+ subgroup. 
Frequency and Pathology of Rejection 
No grafts were lost to acute or chronic rejection in ei-
ther the pretreatment or conventional treatment series. The 
incidence of chronic rejection in both groups was zero. Dur-
ing the first 4 months, the overall rate of first onset acute 
rejection was 10% in the alemtuzumab-pretreated patients 
compared with 20% in the conventionally treated patients 
(P=0.56, NS). Only 6% of the HCV+ recipients pretreated 
with alemtuzumab developed first rejection during the first 4 
months after transplantation compared with 30% in the con-
ventional group (P=O.lO). 
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FIGURE 3. Viral replication to 37.7 million ru/mL 2 
months after alemtuzumab pretreatment and liver trans-
plantation. The viral load (open squares) returned to base-
line for the next half year coincident with drug weaning. 
Then, a repeat dose of alemtuzumab was followed by a viral 
crisis (92 million IU) that subsequently subsided. Although 
the patient is clinically well and back on spaced weaning, 
the 14-month biopsy shows bridging fibrosis. 
The major histopathologic features of acute rejection in 
the patients treated with alemtuzumab and minimum immu-
nosuppression were similar to those in the conventionally 
treated recipients. Mixed portal tract or.perivenular inflam-
mation containing blastic lymphocytes, eosinophils, and 
plasma cells, and similar subendothelial infiltration of portal 
vein branches and hepatic venules and bile duct inflamma-
tion and damage were the characteristic features. In some 
patients maintained on little or no steroids, eosinophils com-
prised a significant proportion of the inflammation. 
In several long-term survivors, at least two of whom 
demonstrated HCV, intense plasmacytic interface activity 
was noted that resembled autoimmune hepatitis. In these 
cases, it was difficult to distinguish among viral immunity, 
alloimmunity, and autoimmunity. Although fmdings of an-
tibody-mediated rejection were not conspicuous in most re-
jection episodes, a systematic investigation of antidonor an-
tibodies and C4d deposits in the liver allografts is currently 
under investigation. 
It is noteworthy that class I and II antibodies did not 
develop de novo in 32 of 41 alemtuzumab-pretreated recipi-
ents of crossmatch negative recipients in whom sequential 
serum samples were obtained. The other nine patients had 
one or more samples that contained new class I or II antibod-
ies, or both. The new antibodies were detected before spaced 
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TABLE 3. Incidence and extent of weaning 
Alemtuzumab pretreated 
Immunosuppression dosing regimen HCY+ HCY-
Total ali vel entered 
Daily multidrug therapy 
Daily monotherapy 
Every other day 
3/wk 
2/wk 
l/wk 
Every 2 weeks 
Off immunosuppression 
27/38 (71.5%) 
2 
6 
10 
3 
4 
1 
'1 
weaning in some cases and afterward in others. One of the 
nine patients died of recurrent HCY. Three of the other eight 
patients are on spaced weaning, whereas five are on daily 
doses. 
Incidence of Weaning 
Of the surviving 64 alemtuzumab-pretreated recipi-
ents, only 5 (7.8%) are receiving more than one drug 14 to 22 
months after transplantation. Sixteen patients (25%) are re-
ceiving daily monotherapy (14 receiving tacrolimus and 2 
receiving cyclosporine). Another 39 patients (62%) are re-
ceiving spaced doses of monotherapy (35 receiving tacroli-
mus, 3 receiving cyclosporine, and 1 receiving sirolimus) at 
intervals ranging from every other day to once every 2 weeks. 
Four patients are not receiving immunosuppression (Table 
3). The incidence of spaced or complete weaning in the se-
verely reduced HCY+ recipient population is approximately 
the same as that in the nearly intact HCY- cohort (67% vs. 
65%). Weaning was not systematically attempted in the con-
ventionally treated patients (Table 3). 
DISCUSSION 
The management plan into which alemtuzumab was 
incorporated was based on the concept that immunosuppres-
sion-assisted organ engraftment is a form of variable donor-
specific tolerance (J, 11). In this paradigm, the seminalmech-
anism of alloengraftment is activation and exhaustiori-
deletion of the clonal response induced in the first few 
postoperative weeks by migration of the transplanted organ's 
passenger leukocytes to the recipient's lymphoid organs. The 
purpose oflymphoid depletion in advance of transplantation 
was to reduce global immune reactivity before exposing the 
recipient to alloantigen and to thereby bring the anticipated 
donor specific response into a more readily deletable range 
(Fig. lB). 
The superior qualities and safety of antilymphoid prep-
arations for pretransplant conditioning have been known 
since the 1960s (12-14). The experience compiled elsewhere 
(5-9) and reported here has established alemtuzumab as a 
premiere antilymphoid antibody agent. But neither the opti-
mal timing nor the long-term consequences oflymphoid de-
pletion have been fully clarified (15, 16). In the other centers, 
two doses of alemtuzumab were given: the first intraopera-
tively and the second in the posttransplant period. With this 
37/38 (97%) 
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strategy, a low incidence of rejection and a reduced depen-
dence on maintenance immunosuppression were observed 
(5-9). In the frame of reference shown in Figure lA, it is 
conceivable that administration of alemtuzumab in the post-
operative period could variably erode the seminal mechanism 
of clonal exhaustion-deletion in the same way as multidrug 
therapy. If so, late weaning may be precluded. 
The more immediate question that has emerged 
from the experience reported here concerns the effect of 
immunosuppression in patients with HCY. The combined 
use of pretransplant lymphoid depletion with alemtu-
zumab and minimalistic posttransplant immunosuppres-
sion provided excellent results and allowed a high rate of 
spaced weaning in patients whose original disease was not 
caused by HCY. Although spaced weaning also could be 
performed in the majority of surviving HCY+ patients, a 
large number of HCY+ patients either died early from a 
variety ofnon-HCY infections or of HCY-associated graft 
dysfunction that frequently followed viral replication. The 
adverse consequences of HCY also were apparent to a 
greater extent than reported in some other centers (17, 18) 
in our patients treated with conventional immunosup-
pression. Although the excessive mortality in our conven-
tionally treated HCY+ patients may have been associated 
with the liberal use of steroids and other adjunct agents 
(17, 19), the major risk factor in the alemtuzumab-pre-
treated HCY+ recipients clearly was lymphoid depletion. 
Because HCV-associated disease has become the single 
most frequent indication for liver transplantation, finding the 
best treatment for these recipients has become a high priority. 
Having concluded from the experience reported here that 
pretransplant lymphoid depletion may contribute to HCY+ 
recurrence, we are currently exploring the strategy of using 
the principle of minimal immunosuppression alone (Fig. 
1 C). Although the incidence of rejection predictably will be 
higher, acute rejection per se has been shown not to degrade 
the late results in the large Pittsburgh series ofliver recipients 
(20). Whether the same is true of the HCY+ subgroup of 
patients in this collection remains to be determined. 
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